Search
Our connected CDMO and CRO capabilities across the drug development journey can help advance your program from molecule to medicine to market, faster.
We support your asset development with our decades of CDMO and CRO—or CRDMO—expertise. Thermo Fisher Scientific offers an end-to-end suite of drug development and clinical trial solutions spanning drug substance and drug product manufacturing for small molecules, large molecules, and advanced therapies, as well as supply chain, clinical research, and commercialization services.
Our unique, fully integrated approach ensures collaboration across the drug development ecosystem, helping to enable increased speed, simplicity, and scalability.
Click on any of the above 3 drug development phases to learn how your journey can be streamlined.
Value reimagined:
Unlocking ROI and efficiency in drug development
New research from the Tufts Center for the Study of Drug Development quantifies the positive value of aligning CDMO, CRO, clinical supply, and lab services through a single partner. The findings: streamlined execution, faster timelines, and up to 113x ROI.
Discover how Thermo Fisher Scientific can help you reduce complexity, gain benefits, and streamline your unique drug development journey.
Decades of experience bringing innovative therapies to market globally.
We recognize the need to continually evolve and closely partner with our customers to support them throughout their journey of bringing innovative medicines to market.
Hear from the experts you’ll meet along your journey:
Frequently asked questions (FAQs)
Yes, Thermo Fisher Scientific offers a full suite of integrated CDMO and CRO services. The Patheon™ CDMO pharma services provides drug development, clinical trial supply and logistics, and commercial manufacturing. The PPD™ clinical research business of Thermo Fisher Scientific is a leading provider of global contract research organization (CRO) solutions.
Accelerator™ Drug Development from Thermo Fisher Scientific combines CDMO and CRO capabilities under a single outsourcing partner to help streamline drug development, manufacturing, and clinical research. Watch our overview video here.
By coordinating CDMO and CRO services through one partner, Accelerator™ Drug Development by Thermo Fisher Scientific helps biotech and pharma companies simplify program management, reduce vendor handoffs, proactively manage risk, and speed up development timelines while providing the scalability needed as programs advance. Learn more about how we can drive speed in this white paper.
A contract development and manufacturing organization (CDMO) is a company that provides outsourced drug development and manufacturing services to biotechnology and pharmaceutical companies. The wide range of CDMO offerings may include formulation, clinical and commercial manufacturing, regulatory support, product packaging, supply chain management, quality assurance, and technology transfer solutions. A clinical research organization (CRO) supports biotechnology and pharmaceutical companies by managing and conducting various aspects of clinical research, such as clinical trial design, site selection, patient recruitment, clinical monitoring, data management, medical writing, and project management. A CRDMO, or contract research, development, and manufacturing organization, is a type of outsourcing partner that combines the services traditionally offered by CDMOs and CROs—integrated from end to end. CRDMOs provide a comprehensive suite of capabilities for drug development, encompassing initial research, clinical trials, development, manufacturing, and supply chain management. Learn more here.
Integrating contract development and manufacturing organization (CDMO) services and contract research organization (CRO) services can help sponsors reduce the complexity that often comes with managing multiple vendors across drug development. A more connected approach may support faster timelines, fewer handoffs, and improved coordination from early development through commercialization. Read our white paper based on a study by the Tufts Center for the Study of Drug Development to learn more about the benefits of integration.